|
Mechanismfungal CYP51A1 inhibitors |
|
Originator Org.- |
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.ES |
First Approval Date10 Mar 1995 |
Target- |
MechanismMediator release inhibitors |
|
Originator Org.- |
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.JP |
First Approval Date01 Jan 1987 |
Target- |
|
|
Originator Org.- |
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价注射用重组人凝血因子Ⅷ-Fc融合蛋白(FRSW107)在重型血友病A儿童患者中的药代动力学、安全性和耐受性的开放、单次给药Ⅰ期临床研究
[Translation] An open-label, single-dose phase I clinical study to evaluate the pharmacokinetics, safety and tolerability of recombinant human factor VIII-Fc fusion protein for injection (FRSW107) in children with severe hemophilia A
评价注射用重组人凝血因子Ⅷ-Fc融合蛋白(FRSW107)在重型血友病A儿童患者中的药代动力学(PK)特征。
评价注射用重组人凝血因子Ⅷ-Fc融合蛋白(FRSW107)在重型血友病A儿童患者中的安全性和耐受性。
[Translation] To evaluate the pharmacokinetic (PK) characteristics of recombinant human factor VIII-Fc fusion protein for injection (FRSW107) in children with severe hemophilia A.
To evaluate the safety and tolerability of recombinant human factor VIII-Fc fusion protein for injection (FRSW107) in children with severe hemophilia A.
注射用重组人凝血因子VIII-Fc融合蛋白治疗血友病A患者(成人及青少年)有效性和安全性的单臂、开放、多中心的III期扩展试验
[Translation] A single-arm, open-label, multicenter phase III extension trial of the efficacy and safety of recombinant human coagulation factor VIII-Fc fusion protein for injection in patients with hemophilia A (adults and adolescents)
进一步评价注射用重组人凝血因子Ⅷ-Fc融合蛋白在血友病A受试者中进行预防治疗的有效性和安全性。
[Translation] To further evaluate the efficacy and safety of recombinant human coagulation factor VIII-Fc fusion protein for injection in the prophylactic treatment of hemophilia A subjects.
注射用重组人凝血因子VIII-Fc融合蛋白治疗血友病A患者(成人及青少年)有效性和安全性的单臂、开放、多中心临床试验
[Translation] A single-arm, open-label, multicenter clinical trial of the efficacy and safety of recombinant human coagulation factor VIII-Fc fusion protein for injection in patients with hemophilia A (adults and adolescents)
主要目的:评价注射用重组人凝血因子VIII-Fc融合蛋白在血友病A受试者中进行按需和预防治疗的有效性。 次要目的:评价注射用重组人凝血因子VIII-Fc融合蛋白用于血友病A受试者的止血效果、预防出血效果、生存质量及安全性。
[Translation] Main objective: To evaluate the efficacy of recombinant human coagulation factor VIII-Fc fusion protein for injection in on-demand and prophylactic treatment in hemophilia A subjects. Secondary objective: To evaluate the hemostatic effect, prevention effect, quality of life and safety of recombinant human coagulation factor VIII-Fc fusion protein for injection in subjects with hemophilia A.
100 Clinical Results associated with Kaifeng Pharmaceutical (Group) Co., Ltd.
0 Patents (Medical) associated with Kaifeng Pharmaceutical (Group) Co., Ltd.
05 Nov 2013·Zhongguo Yaoye
Determination of antioxidant content in Bromfenac Sodium Eye Drops
Author: Zhang, Zhiming ; Fu, Xiaoning
A determination method for antioxidant sodium sulfite in Bromfenac Sodium Eye Drops was established. The UV spectrophotometry method was adopted. Fuchsia complex compound generated by sodium sulfite and fuchsin basic under the acidic condition was determined the absorbance at the wave length of 560 nm. Then the content of sodium sulfite was calculated This product within the range of 0.3-2.2 μg/mL showed the good linear relation with the peak area (r=0.999 4). The average recovery rate was 9.7% with RSD=1.31%. This method is simple and accurate for determination of antioxidant sodium sulfite in Bromfenac Sodium Eye Drops.
20 Mar 2013·Linchuang Yixue
Compatible stability of chloramphenicol injection and potassium sodium dehydroandrographolide succinate for injection
Author: Lin, Heng-kuan ; Lin, Heng-dao
The aim of this paper is to evaluate compatible stability of chloramphenicol injection and potassium sodium dehydroandrographolide succinate for injection. The content change of chloramphenicol injection and compatibility with potassium sodium dehydroandrographolide succinate for injection in 0-6 h were simultaneous determined by HPLC method. There were no significant changes in the mixed solution within 6 h. Chloramphenicol injection and potassium sodium dehydroandrographolide succinate for injection can be used together.
100 Deals associated with Kaifeng Pharmaceutical (Group) Co., Ltd.
100 Translational Medicine associated with Kaifeng Pharmaceutical (Group) Co., Ltd.